Stéphane Richard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7113885/publications.pdf

Version: 2024-02-01

36303 24258 12,438 119 51 110 citations h-index g-index papers 132 132 132 12125 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Novel germline <i>MET pathogenic variants in French patients with papillary renal cell carcinomas type I</i> i>. Human Mutation, 2022, 43, 316-327.	2.5	8
2	MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features. Modern Pathology, 2021, 34, 647-659.	5 . 5	16
3	Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma. European Journal of Cancer, 2021, 151, 106-114.	2.8	18
4	Germline mutation in the NBR1 gene involved in autophagy detected in a family with renal tumors. Cancer Genetics, 2021, 258-259, 51-56.	0.4	5
5	Involvement of PBRM1 in VHL disease†associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway. Oncology Letters, 2021, 22, 835.	1.8	5
6	Clear cell and papillary renal cell carcinomas in hereditary papillary renal cell carcinoma (HPRCC) syndrome: a case report. Diagnostic Pathology, 2021, 16, 107.	2.0	2
7	Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients. Theranostics, 2020, 10, 2696-2713.	10.0	12
8	Germline mutations in the new E1' cryptic exon of the <i>VHL</i> gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma. Journal of Medical Genetics, 2020, 57, 752-759.	3.2	12
9	iPSC-Derived Embryoid Bodies as Models of c-Met-Mutated Hereditary Papillary Renal Cell Carcinoma. International Journal of Molecular Sciences, 2019, 20, 4867.	4.1	23
10	Optimization of Next-Generation Sequencing Technologies for von Hippel Lindau (VHL) Mosaic Mutation Detection and Development of Confirmation Methods. Journal of Molecular Diagnostics, 2019, 21, 462-470.	2.8	16
11	Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration. Modern Pathology, 2018, 31, 974-983.	5.5	65
12	Pathological heterogeneity in sporadic synchronous renal tumors: Is the histological concordance predictable?. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 11.e7-11.e12.	1.6	7
13	Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease. International Journal of Oncology, 2018, 53, 1455-1468.	3.3	9
14	Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. Blood, 2018, 132, 469-483.	1.4	70
15	Biphasic Squamoid Alveolar Renal Cell Carcinoma: 2 Cases in a Family Supporting a Continuous Spectrum With Papillary Type I Renal Cell Carcinoma. American Journal of Surgical Pathology, 2017, 41, 1011-1012.	3.7	26
16	Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French <i><scp>FH</scp></i> mutation carriers. Clinical Genetics, 2017, 92, 606-615.	2.0	103
17	Laser Photocoagulation for Peripheral Retinal Capillary Hemangioblastoma in von Hippel-Lindau Disease. Ophthalmology Retina, 2017, 1, 59-67.	2.4	18
18	Characterization of endolymphatic sac tumors and von Hippel–Lindau disease in the International Endolymphatic Sac Tumor Registry. Head and Neck, 2016, 38, E673-9.	2.0	48

#	Article	IF	CITATIONS
19	Surgical resection of medulla oblongata hemangioblastomas: outcome and complications. Acta Neurochirurgica, 2016, 158, 1333-1341.	1.7	12
20	Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome. Journal of Clinical Oncology, 2016, 34, 2172-2181.	1.6	132
21	Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel–Lindau Gene Mutation Status. European Urology, 2016, 70, 623-632.	1.9	115
22	Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group. Oncotarget, 2016, 7, 85306-85317.	1.8	22
23	Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place. Annals of Surgery, 2015, 262, 384-388.	4.2	46
24	A germline mutation in <i>PBRM1</i> predisposes to renal cell carcinoma. Journal of Medical Genetics, 2015, 52, 426-430.	3.2	38
25	Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2. Anticancer Research, 2015, 35, 6639-53.	1.1	14
26	The role of PHD2 mutations in the pathogenesis of erythrocytosis. Hypoxia (Auckland, N Z), 2014, 2, 71.	1.9	39
27	Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Familial Cancer, 2014, 13, 637-644.	1.9	251
28	Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases. Human Mutation, 2014, 35, 15-26.	2.5	101
29	Renal cell tumour characteristics in patients with the Birt-Hogg-Dubé cancer susceptibility syndrome: a retrospective, multicentre study. Orphanet Journal of Rare Diseases, 2014, 9, 163.	2.7	78
30	Genetic Evidence of a Precisely Tuned Dysregulation in the Hypoxia Signaling Pathway during Oncogenesis. Cancer Research, 2014, 74, 6554-6564.	0.9	32
31	Management of Endolymphatic Sac Tumors. Otology and Neurotology, 2014, 35, 899-904.	1.3	35
32	Germline BAP1 Mutations Predispose to Renal Cell Carcinomas. American Journal of Human Genetics, 2013, 92, 974-980.	6.2	239
33	Von Hippel–Lindau: How a rare disease illuminates cancer biology. Seminars in Cancer Biology, 2013, 23, 26-37.	9.6	93
34	Letter to the Editor: Pregnancy and von Hippel-Lindau disease. Journal of Neurosurgery, 2013, 118, 1380-1382.	1.6	4
35	Telomere crisis in kidney epithelial cells promotes the acquisition of a microRNA signature retrieved in aggressive renal cell carcinomas. Carcinogenesis, 2013, 34, 1173-1180.	2.8	19
36	Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients. Clinical Cancer Research, 2012, 18, 2838-2849.	7.0	61

#	Article	IF	CITATIONS
37	Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. Haematologica, 2012, 97, 9-14.	3.5	50
38	Von Hippel-Lindau disease and aggressive GH-PRL pituitary adenoma in a young boy. Annales D'Endocrinologie, 2012, 73, 37-42.	1.4	14
39	Vitreoretinal Surgery for Severe Retinal Capillary Hemangiomas in Von Hippel–Lindau Disease. Ophthalmology, 2011, 118, 142-149.	5 . 2	73
40	A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature, 2011, 480, 94-98.	27.8	466
41	Progress in Nephron Sparing Therapy for Renal Cell Carcinoma and von Hippel-Lindau Disease. Journal of Urology, 2011, 185, 2056-2060.	0.4	38
42	von Hippel–Lindau disease: A clinical and scientific review. European Journal of Human Genetics, 2011, 19, 617-623.	2.8	588
43	Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature, 2011, 469, 539-542.	27.8	1,127
44	An Antioxidant Response Phenotype Shared between Hereditary and Sporadic Type 2 Papillary Renal Cell Carcinoma. Cancer Cell, 2011, 20, 511-523.	16.8	347
45	Conservative management of endolymphatic sac tumors in von Hippel–Lindau disease: case report. Acta Neurochirurgica, 2011, 153, 42-47.	1.7	10
46	Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. Journal of Medical Genetics, 2011, 48, 226-234.	3.2	116
47	Abstract 3820: Deregulation of KEAP1-NRF axis in phenotypically type 2 papillary renal cell carcinoma. , $2011, \ldots$		0
48	Difficult Diagnosis of Atypical Cystic Pancreatic Lesions in von Hippel-Lindau Disease. Journal of Computer Assisted Tomography, 2010, 34, 140-145.	0.9	7
49	Natural History of Supratentorial Hemangioblastomas in von Hippel-Lindau Disease. Neurosurgery, 2010, 67, 577-587.	1.1	42
50	Radiofrequency ablation of renal tumours: diagnostic accuracy of contrast-enhanced ultrasound for early detection of residual tumour. European Radiology, 2010, 20, 1812-1821.	4.5	53
51	No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome. Familial Cancer, 2010, 9, 245-251.	1.9	26
52	Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer, 2010, 10, 196.	2.6	86
53	A new locus-specific database (LSDB) for mutations in the folliculin (<i>FLCN</i>) gene. Human Mutation, 2010, 31, E1043-E1051.	2.5	93
54	Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression. BMC Medical Genomics, 2010, 3, 59.	1.5	68

#	Article	IF	CITATIONS
55	Novel <i>FH</i> mutation in a patient with cutaneous leiomyomatosis associated with cutis verticis gyrata, eruptive collagenoma and Charcot-Marie-Tooth disease. British Journal of Dermatology, 2010, 163, 1337-1339.	1.5	8
56	The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 492-499.	1.6	42
57	Endolymphatic Sac Tumors in von Hippel-Lindau Disease. Otology and Neurotology, 2010, 31, 660-664.	1.3	13
58	Supratentorial Hemangioblastoma in the Neonatal Period. Pediatric Neurosurgery, 2009, 45, 155-156.	0.7	4
59	Head and Neck Paragangliomas in Von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1938-1944.	3.6	112
60	Axitinib Induces Paradoxical Erythropoietin Synthesis in Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2009, 27, 472-473.	1.6	23
61	Results of microsurgical treatment of medulla oblongata and spinal cord hemangioblastomas: a comparison of two distinct clinical patient groups. Journal of Neuro-Oncology, 2009, 93, 133-137.	2.9	37
62	Maladie de von Hippel-Lindau. , 2009, , 179-182.		0
63	Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncology, The, 2009, 10, 1199-1206.	10.7	509
64	Pancreatic Endocrine Microadenomatosis in Patients With von Hippel-Lindau Disease. American Journal of Surgical Pathology, 2009, 33, 739-748.	3.7	60
65	Analysis of the <i>DND1</i> gene in men with sporadic and familial testicular germ cell tumors. Genes Chromosomes and Cancer, 2008, 47, 247-252.	2.8	37
66	Novel somatic mutations of the VHL gene in an erythropoietin-producing renal carcinoma associated with secondary polycythemia and elevated circulating endothelial progenitor cells. American Journal of Hematology, 2008, 83, 155-158.	4.1	13
67	A comparison study reveals important features of agreement and disagreement between summarized DNA and RNA data obtained from renal cell carcinoma. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2008, 657, 77-83.	1.7	3
68	Somatic Pairing of Chromosome 19 in Renal Oncocytoma Is Associated with Deregulated ELGN2-Mediated Oxygen-Sensing Response. PLoS Genetics, 2008, 4, e1000176.	3.5	58
69	Familial Non-VHL Clear Cell (Conventional) Renal Cell Carcinoma: Clinical Features, Segregation Analysis, and Mutation Analysis of <i>FLCN</i> . Clinical Cancer Research, 2008, 14, 5925-5930.	7.0	64
70	Combined <i>Vhlh</i> and <i>Pten</i> Mutation Causes Genital Tract Cystadenoma and Squamous Metaplasia. Molecular and Cellular Biology, 2008, 28, 4536-4548.	2.3	41
71	<i>PHD2</i> Mutation and Congenital Erythrocytosis with Paraganglioma. New England Journal of Medicine, 2008, 359, 2685-2692.	27.0	284
72	Endocrine Pancreatic Tumors in von Hippel-Lindau Disease. Pancreas, 2008, 37, 85-93.	1.1	75

#	Article	IF	Citations
73	Local Recurrence After Nephron-Sparing Surgery in von Hippel-Lindau Disease. Urology, 2007, 70, 435-439.	1.0	40
74	Trichloroethylene exposure and somatic mutations of the VHL gene in patients with Renal Cell Carcinoma. Journal of Occupational Medicine and Toxicology, 2007, 2, 13.	2.2	23
75	Mutations in BHD and TP53 genes, but not in HNF1 \hat{l}^2 gene, in a large series of sporadic chromophobe renal cell carcinoma. British Journal of Cancer, 2007, 96, 336-340.	6.4	65
76	Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results. Targeted Oncology, 2007, 2, 3-6.	3.6	20
77	A novel familial germline mutation in the initiator codon of the BHD gene in a patient with Birt-Hogg-Dubé syndrome. British Journal of Dermatology, 2006, 155, 1067-1069.	1.5	29
78	Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Human Molecular Genetics, 2006, 15, 443-451.	2.9	138
79	Protection of p27Kip1 mRNA by quaking RNA binding proteins promotes oligodendrocyte differentiation. Nature Neuroscience, 2005, 8, 27-33.	14.8	151
80	Genetic Testing in Pheochromocytoma or Functional Paraganglioma. Journal of Clinical Oncology, 2005, 23, 8812-8818.	1.6	612
81	The Y Deletion gr/gr and Susceptibility to Testicular Germ Cell Tumor. American Journal of Human Genetics, 2005, 77, 1034-1043.	6.2	197
82	Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clinical Cancer Research, 2005, 11, 1059-64.	7.0	38
83	The growing family of hereditary renal cell carcinoma. Nephrology Dialysis Transplantation, 2004, 19, 2954-2958.	0.7	21
84	Somatic mutations of KIT in familial testicular germ cell tumours. British Journal of Cancer, 2004, 90, 2397-2401.	6.4	85
85	Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. Human Mutation, 2004, 24, 215-224.	2.5	81
86	High incidence of renal tumours in vitamins A and E synthesis workers: A new cause of occupational cancer?. International Journal of Cancer, 2004, 108, 942-944.	5.1	14
87	Von Hippel-Lindau disease. Lancet, The, 2004, 363, 1231-1234.	13.7	106
88	Pancreatic Involvement in Von Hippel-Lindau Disease. , 2004, , 144-152.		4
89	A type 2B von Hippel-Lindau family masquerading as a metastatic sporadic renal cell carcinoma. BJU International, 2003, 91, 425-426.	2.5	3
90	Nephron Sparing Surgery for Renal Cell Carcinoma and von Hippel-Lindau's Disease: A Single Center Experience. Journal of Urology, 2003, 170, 1752-1755.	0.4	37

#	Article	IF	CITATIONS
91	Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. American Journal of Ophthalmology, 2003, 136, 194-196.	3.3	109
92	von Hippel-Lindau disease: recent advances and therapeutic perspectives. Expert Review of Anticancer Therapy, 2003, 3, 215-233.	2.4	21
93	Spectrum of Abdominal Imaging Findings in von Hippel-Lindau Disease. American Journal of Roentgenology, 2003, 181, 1049-1054.	2.2	49
94	Inactivation of BHD in sporadic renal tumors. Cancer Research, 2003, 63, 4583-7.	0.9	96
95	Radiology Quiz Case. JAMA Otolaryngology, 2002, 128, 855.	1.2	2
96	Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti–vascular endothelial growth factor receptor therapy. Blood, 2002, 99, 3851-3853.	1.4	50
97	Diagnosis of pheochromocytoma and laparoscopic adrenalectomy in two anephric patients with von hippel-lindau disease. American Journal of Kidney Diseases, 2002, 39, e6.1-e6.4.	1.9	4
98	Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Investigative Ophthalmology and Visual Science, 2002, 43, 3067-74.	3.3	91
99	Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease. Neurosurgical Review, 2000, 23, 1-22.	2.4	147
100	Attitudes of von Hippel-Lindau disease patients towards presymptomatic genetic diagnosis in children and prenatal diagnosis. Journal of Medical Genetics, 2000, 37, 476-479.	3.2	22
101	Pancreatic involvement in von Hippel–Lindau disease. Gastroenterology, 2000, 119, 1087-1095.	1.3	374
102	Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 1999, 18, 2343-2350.	5.9	487
103	Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC. Human Mutation, 1999, 13, 464-475.	2.5	126
104	Long polymerase chain reaction in detection of germline deletions in the von Hippel-Lindau tumour suppressor gene. Human Genetics, 1999, 105, 333-336.	3.8	18
105	Germline mutation profile of theVHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma. Human Mutation, 1998, 12, 424-430.	2.5	89
106	Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics, 1997, 16, 68-73.	21.4	1,461
107	Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. American Journal of Human Genetics, 1997, 60, 765-71.	6.2	149
108	Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Human Mutation, 1996, 8, 348-357.	2.5	436

#	Article	IF	CITATIONS
109	Renal involvement in von Hippel-Lindau disease. Kidney International, 1996, 50, 944-951.	5.2	107
110	Germline mutations in the Von Hippel‣indau disease (VHL) gene in families from North America, Europe, and Japan. Human Mutation, 1996, 8, 348-357.	2.5	33
111	Congenital Soft Tissue Dysplasias: A Morphological and Biochemical Study. Pediatric Pathology, 1994, 14, 873-894.	0.5	1
112	Familial cancer syndromes. Lancet, The, 1994, 343, 1222.	13.7	1
113	Microsporidia Infection in Patients with the Human Immunodeficiency Virus and Unexplained Cholangitis. New England Journal of Medicine, 1993, 328, 95-99.	27.0	230
114	Enterocytozoon bieneusi infection in acquired immunodeficiency syndrome-related sclerosing cholangitis. Gastroenterology, 1992, 102, 1778-1781.	1.3	59
115	Allelic loss on chromosome 22 correlates with histopathological predictors of recurrence of meningiomas. International Journal of Cancer, 1992, 50, 391-394.	5.1	30
116	Genotypic differences in hemangiopericytic meningioma. Human Pathology, 1991, 22, 402.	2.0	8
117	Intermitochondrial junctions in a subpopulation of peripheral blood lymphocytes from healthy subjects*. Biology of the Cell, 1990, 70, 27-32.	2.0	2
118	Del cell line: A "malignant histiocytosis―CD30 + T(5;6)(Q35;P21) cell line. International Journal of Cancer, 1990, 45, 546-553.	5.1	19
119	Congenital Ciliary Aplasia in Two Siblings. Pathology Research and Practice, 1989, 185, 181-183.	2.3	10